百心安-B(02185.HK)：IBERISRDN系统在新西兰注册
BIOHEARTBIOHEART(HK:02185) Ge Long Hui A P P·2025-11-26 11:26

Core Viewpoint - The announcement highlights that the Iberis® RDN system developed by the company's subsidiary has received registration from New Zealand's Medsafe, marking a significant milestone in the company's product offerings [1] Company Summary - The Iberis® RDN system is the only renal denervation product globally approved for both transradial access (TRA) and transfemoral access (TFA) methods [1] - TRA enhances the safety, efficacy, and cost-effectiveness of renal denervation procedures [1] - The ultimate goal of the company is to provide outpatient renal denervation surgeries to patients worldwide [1] - The company obtained the CE mark for the Iberis® RDN system in Europe in 2016 [1]